Not Just an Alternative Energy Source: Diverse Biological Functions of Ketone Bodies and Relevance of HMGCS2 to Health and Disease
Open Access
- 14 April 2025
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 15 (4) , 580
Abstract
Ketogenesis, a mitochondrial metabolic pathway, occurs primarily in liver, but kidney, colon and retina are also capable of this pathway. It is activated during fasting and exercise, by “keto” diets, and in diabetes as well as during therapy with SGLT2 inhibitors. The principal ketone body is β-hydroxybutyrate, a widely recognized alternative energy source for extrahepatic tissues (brain, heart, muscle, and kidney) when blood glucose is sparse or when glucose transport/metabolism is impaired. Recent studies have identified new functions for β-hydroxybutyrate: it serves as an agonist for the G-protein-coupled receptor GPR109A and also works as an epigenetic modifier. Ketone bodies protect against inflammation, cancer, and neurodegeneration. HMGCS2, as the rate-limiting enzyme, controls ketogenesis. Its expression and activity are regulated by transcriptional and post-translational mechanisms with glucagon, insulin, and glucocorticoids as the principal participants. Loss-of-function mutations occur in HMGCS2 in humans, resulting in a severe metabolic disease. These patients typically present within a year after birth with metabolic acidosis, hypoketotic hypoglycemia, hepatomegaly, steatotic liver damage, hyperammonemia, and neurological complications. Nothing is known about the long-term consequences of this disease. This review provides an up-to-date summary of the biological functions of ketone bodies with a special focus on HMGCS2 in health and disease.Keywords
All Related Versions
Funding Information
- National Institutes of Health (CA275840)
This publication has 190 references indexed in Scilit:
- Adaptive Metabolic Responses Facilitate Blood‐Brain Barrier Repair in Ischemic Stroke via BHB‐Mediated Epigenetic Modification of ZO‐1 ExpressionAdvanced Science, 2024
- Expanding the clinical spectrum of mitochondrial 3‐hydroxy‐3‐methylglutaryl‐CoA synthase deficiency with Turkish cases harboring novel HMGCS2 gene mutations and literature reviewAmerican Journal of Medical Genetics Part A, 2020
- Mutation update on ACAT1 variants associated with mitochondrial acetoacetyl‐CoA thiolase (T2) deficiencyHuman Mutation, 2019
- Novel HMGCS2 pathogenic variants in a Chinese family with mitochondrial 3‐hydroxy‐3‐methylglutaryl‐CoA synthase deficiencyPediatric Investigation, 2019
- A Japanese case of mitochondrial 3‐hydroxy‐3‐methylglutaryl‐CoA synthase deficiency who presented with severe metabolic acidosis and fatty liver without hypoglycemiaJIMD Reports, 2019
- Short‐Chain Fatty Acid Transporters: Role in Colonic HomeostasisComprehensive Physiology, 2018
- Post-translational modifications in mitochondria: protein signaling in the powerhouseCellular and Molecular Life Sciences, 2016
- Differential Inhibition of HMG-CoA Synthase and Pancreatic Lipase by the Specific Chiral Isomers of β-Lactone DU-6622Biochemical and Biophysical Research Communications, 1999
- Molecular Cloning and Tissue Expression of Human Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA SynthaseArchives of Biochemistry and Biophysics, 1995
- Ketogenic Mitochondrial 3-Hydroxy 3-Methylglutaryl-CoA Synthase Gene Expression in Intestine and Liver of Suckling RatsArchives of Biochemistry and Biophysics, 1993